Clarity is a radiopharmaceutical company developing next-generation products to address the growing need for radiopharmaceuticals in oncology.
Clarity is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the “perfect pairing” of copper-64 and copper-67 for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market.
Clarity has a diverse range of products in clinical trials which address both large indications as well as smaller, rare and orphan indications of cancer. Clarity’s current pipeline of products in clinical development includes:
SARTATE: for the treatment of neuroblastoma, Phase I/IIa; for the diagnosis of NETs, Phase II;
SAR-Bombesin: a pan-cancer treatment product, including for the treatment of breast cancer and prostate cancer;
SAR-bisPSMA: for the treatment of prostate cancer, Phase I/IIa in the US; for the diagnosis of prostate cancer, Phase I/II in the US, IIT Phase I/II in the US, Phase I in AUS.